Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII

M. T. Reding, H. J. Ng, L. H. Poulsen, M. E. Eyster, I. Pabinger, H. J. Shin, R. Walsch, M. Lederman, M. Wang, M. Hardtke, L. A. Michaels

Research output: Contribution to journalArticle

43 Scopus citations

Abstract

Essentials Recombinant factor VIII BAY 94-9027 conjugates in a site-specific manner with polyethylene glycol. BAY 94-9027 was given to patients with severe hemophilia A as prophylaxis and to treat bleeds. BAY 94-9027 prevented bleeds at dose intervals up to every 7 days and effectively treated bleeds. BAY 94-9027 treatment was mainly well tolerated and no patient developed factor VIII inhibitors. Click to hear Dr Tiede's perspective on half-life extended factor VIII for the treatment of hemophilia A. Summary: Background BAY 94-9027 is a B-domain-deleted prolonged-half-life recombinant factor VIII (FVIII) that conjugates in a site-specific manner with polyethylene glycol. Objective Assess efficacy and safety of BAY 94-9027 for prophylaxis and treatment of bleeds in patients with severe hemophilia A. Patients/methods In this multinational, phase 2/3, partially randomized, open-label trial, men aged 12–65 years with FVIII < 1% and ≥ 150 exposure days to FVIII received BAY 94-9027 for 36 weeks on demand or prophylactically at intervals determined following a 10-week run-in period on 25 IU kg−1 body weight two times per week. Patients with > 1 bleed during the run-in subsequently received 30–40 IU kg−1 two times per week; patients with ≤ 1 bleed were eligible for randomization to every-5-days (45–60 IU kg−1) or every-7-days (60 IU kg−1) prophylaxis (1 : 1) for 26 additional weeks until randomization arms were filled. Patients who were eligible but not randomized continued twice-weekly prophylaxis. The primary efficacy outcome was annualized bleeding rate (ABR). Results The intent-to-treat population included 132 patients (prophylaxis, n = 112; on demand, n = 20). Median ABR (quartile [Q1; Q3]) for patients treated two times per week who were not eligible for randomization (n = 13) improved after dose increase (17.4 [14.3; 26.0] to 4.1 [2.0; 10.6]). Median ABR for patients randomized to every-5-days treatment (n = 43) was 1.9 (0; 4.2), similar to patients eligible for randomization but who continued treatment two times per week (n = 11). Median ABR for 32/43 patients (74%) who continued every-7-days prophylaxis until study end was 0.96 (0.0; 4.3). Six hundred and thirty-six of 702 bleeds (90.6%) were controlled with ≤ 2 infusions. No patient developed a FVIII inhibitor. Conclusions BAY 94-9027 prevented bleeding across three individually tailored dose regimens and was effective for treatment of bleeds.

Original languageEnglish (US)
Pages (from-to)411-419
Number of pages9
JournalJournal of Thrombosis and Haemostasis
Volume15
Issue number3
DOIs
StatePublished - Mar 1 2017

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII'. Together they form a unique fingerprint.

  • Cite this

    Reding, M. T., Ng, H. J., Poulsen, L. H., Eyster, M. E., Pabinger, I., Shin, H. J., Walsch, R., Lederman, M., Wang, M., Hardtke, M., & Michaels, L. A. (2017). Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII. Journal of Thrombosis and Haemostasis, 15(3), 411-419. https://doi.org/10.1111/jth.13597